Ganymed - PDFSEARCH.IO - Document Search Engine

Ganymed
Results: 81

#	Item
21	Press Release ATS acquires majority shareholding in GANYMED August 21, 2008, Mainz - GANYMED Pharmaceuticals AG today announced the sale of a majority of the company shares to ATS. The shares that have been sold to ATS Add to Reading List Source URL: www.ganymed-pharmaceuticals.com - Date: 2015-02-12 08:20:13
22	Microsoft Word - PressRelease-English-18-4-2007_07_Final.doc Add to Reading List Source URL: www.ganymed-pharmaceuticals.com - Date: 2015-02-04 05:15:00
23	Pressemitteilung 2_Tag der offenen Tür Add to Reading List Source URL: www.ganymed-pharmaceuticals.com - Date: 2015-02-04 05:15:03
24	Microsoft Word - 20160419_Pub List_Dr. Ö.Türeci MD.DOC Add to Reading List Source URL: www.ganymed-pharmaceuticals.com - Date: 2016-05-03 07:38:46
25	Press Release GANYMED verlängert Zusammenarbeit mit dem Kantonsspital St. Gallen Mainz, 18. November 2003 GANYMED Pharmaceuticals AG ist ein unabhängiges Unternehmen in der Biotechnologie, das humane Antigene identifiz Add to Reading List Source URL: www.ganymed-pharmaceuticals.com Language: German - Date: 2015-02-04 05:15:05
26	Ganymed Pharmaceuticals AG ist ein unabhängiges, forschendes Biotechnologieunternehmen in Mainz, das hochwirksame Immuntherapeutika gegen neuartige Zielstrukturen zur Behandlung von Krebserkrankungen entwickelt. Unsere Add to Reading List Source URL: www.ganymed-pharmaceuticals.com Language: German - Date: 2016-05-17 04:46:53
27	Geben Sie sich nur mit der besten Software zufrieden. DIE LÖSUNG FÜR IHRE ARZTPRAXIS. Add to Reading List Source URL: www.ganymed.at Language: German - Date: 2015-07-23 07:47:59
28	Microsoft Word - 2006_10_11_de.doc Add to Reading List Source URL: www.ganymed-pharmaceuticals.com Language: German - Date: 2015-02-04 05:14:56
29	Press Release For Immediate Release June 5, 2016 Add to Reading List Source URL: www.ganymed-pharmaceuticals.com Language: English - Date: 2016-06-05 08:04:51 Clinical medicine Medicine Cancer RTT Monoclonal antibodies Antineoplastic drugs Cancer treatments IMAB362 Chemotherapy Ovarian cancer Lung cancer Treatment of cancer
30	Press release Clinical Phase I Results of GANYMED’s iMAB362 Antibody Demonstrate Excellent Safety Mainz, Germany, August 04, A clinical first-in-human Phase I multi center study with GANYMED’s monoclonal anti Add to Reading List Source URL: www.ganymed-pharmaceuticals.com Language: English - Date: 2015-02-04 05:15:07 Medicine Immunology Monoclonal antibodies Clinical medicine Biology Immune system Pathology Biotechnology IMAB362 Cancer Monoclonal antibody therapy Antibody

UPDATE